CNX-1351 is primarily used in the field of oncology research, where it is investigated for its potential as a therapeutic agent in cancer treatment. It is being studied for its ability to inhibit specific pathways involved in tumor growth and progression, making it a candidate for targeted cancer therapies. Researchers are exploring its efficacy in preclinical models to determine its impact on various cancer types, including solid tumors and hematologic malignancies. Additionally, CNX-1351 is being evaluated for its potential to enhance the effectiveness of existing treatments when used in combination therapies. Its application is focused on improving patient outcomes by providing more precise and effective treatment options.